Reproductive dysfunction in women with epilepsy

Neurology

Volumn 61, Issue 6 SUPPL. 2, 2003, Pages

  Isojärvi, Jouko I T ^a  

^a UNIVERSITY OF OULU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CYTOCHROME P450; ETIRACETAM; FELBAMATE; FOLLITROPIN; GABAPENTIN; LAMOTRIGINE; LUTEINIZING HORMONE; ORAL CONTRACEPTIVE AGENT; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN;

AMENORRHEA; ANTICONVULSANT THERAPY; CONTROLLED STUDY; EARLY MENOPAUSE; ENDOCRINE DISEASE; EPILEPSY; FEMALE; HUMAN; HYPERANDROGENISM; HYPERPROLACTINEMIA; HYPOTHALAMUS HYPOPHYSIS GONAD SYSTEM; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; MENSTRUATION DISORDER; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; REPRODUCTION; REVIEW; TESTOSTERONE BLOOD LEVEL; TRANSVAGINAL ECHOGRAPHY; WEIGHT GAIN;

EID: 0141542600     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.61.6_suppl_2.s27     Document Type: Review

References (75)

1. Dansky LV, Andermann E, Andermann F. Marriage and fertility in epileptic patients. Epilepsia 1980;21:261-271.
2. Webber MP, Hauser WA, Ottman R, Annegers JF. Fertility in persons with epilepsy: 1935-1974. Epilepsia 1986;27:746-752.
3. Scupf N, Ottman R. Likelihood of pregnancy in individuals with idiopathic/cryptogenic epilepsy: social and biological influences. Epilepsia 1994;35:750-756.
4. Scupf N, Ottman R. Reproduction among individuals with idiopathic/cryptogenic epilepsy: risk factors for reduced fertility in marriage. Epilepsia 1996;37:833-840.
5. Wallace H, Shorvon S, Tallis R. Age-specific incidence and prevalence rates of treated epilepsy in an unselected population of 2,052,922 and age-specific fertility rates of women with epilepsy. Lancet 1998;352:1970-1973.
6. Herzog AG, Seibel MM, Schomer DL, Vaitukaitis JL, Geschwind N. Reproductive endocrine disorders in men with partial seizures of temporal lobe origin. Arch Neurol 1986;43:347-350.
7. Herzog AG, Seibel MM, Schomer DL, Vaitukaitis JL, Geschwind N. Reproductive endocrine disorders in women with partial seizures of temporal lobe origin. Arch Neurol 1986;43:341-346.
8. Bilo L, Meo R, Nappi C, et al. Reproductive endocrine disorders in women with primary generalized epilepsy. Epilepsia 1988;29:612-619.
9. Isojärvi JIT, Laatikainen TJ, Pakarinen AJ, Juntunen KTS, Myllylä VV. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N Engl J Med 1993;329:1383-1388.
10. Trimble MR, Dana-Haeri J, Oxley J, Baylis PH. Some neuroendocrine consequences of seizures. In: Porter RJ, Ward AA Jr, Mattson RH, Dam M, eds. Advances in epileptology: the XVth Epilepsy International Symposium. New York: Raven Press, 1984:210-218.
11. Isojärvi JIT, Pakarinen AJ, Ylipalosaari PJ, Myllylä VV. Serum hormones in male epileptic patients receiving anticonvulsant medication. Arch Neurol 1990;47:670-676.
12. Yen SSC. Polycystic ovary syndrome (hyperandrogenic chronic anovulation). In: Yen SSC, Jaffe RB, Barbieri RL, eds. Reproductive endocrinology. 4th ed. Philadelphia: WB Saunders, 1999;436-478.
13. Knochenhauser ES, Key TJ, Kashar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 1998;83:3078-3082.
14. Herzog AG, Schachter SC. Valproate and the polycystic ovarian syndrome: final thoughts. Epilepsia 2001;42:311-315.
15. Herzog AG, Seibel MM, Schomer D, Vaitukaitis J, Geschwind N. Temporal lobe epilepsy: an extrahypothalamic pathogenesis for polycystic ovarian syndrome? Neurology 1984;34:1389-1393.
16. Klein P, Serje A, Pezzullo JC. Premature ovarian failure in women with epilepsy. Epilepsia 2001;42:1584-1589.
17. Bauer J, Stefan H, Schrell U, et al. Serum prolactin concentrations and epilepsy. A study which compares healthy subjects with a group of patients in presurgical evaluation and circadian variations with those related to seizures. Eur Arch Psychiatry Clin Neurosci 1992;241:365-371.
18. Bauer J. Epilepsy and prolactin in adults: a clinical review. Epilepsy Res 1996;24:1-7.
19. Molaie M, Culebras A, Miller M. Effect of interictal epileptiform discharges on nocturnal plasma prolactin concentrations in epileptic patients with complex partial seizures. Epilepsia 1986;27:724-728.
20. Oppenheimer JH, Fischer LV, Nielson KM, Jailer JW. Depression of the serum protein-bound iodine level by diphenylhydantoin. J Clin Endocrinol Metab 1961;21:252-262.
21. Fichsel H, Knöpfle G. Effects of anticonvulsant drugs on thyroid hormones in epileptic children. Epilepsia 1978;19:323-336.
22. Liewendahl K, Majuri H, Helenius T. Thyroid function test in patients on long-term treatment with various anticonvulsant drugs. Clin Endocrinol 1978;8:185-191.
23. Rootwelt K, Ganes T, Johannesen SI. Effect of carbamazepine, phenytoin and phenobarbital on serum levels of thyroid hormones and thyrotropin in humans. Scand J Clin Lab Invest 1978;38:731-736.
24. Strandjord RE, Aanderud S, Myking OL, Johannesen SI. Influence of carbamazepine on serum thyroxine and triiodothyronine in patients with epilepsy. Acta Neurol Scand 1981;63:111-121.
25. Beastall GH, Cowan RA, Gray JMB, Fogelman I. Hormone binding globulins and anticonvulsant therapy. Scott Med J 1985;30:101-105.
26. Macphee GJ, Larkin JG, Butler E, Beastall GH, Brodie MJ. Circulating hormones and pituitary responsiveness in young epileptic men receiving long-term antiepileptic medication. Epilepsia 1988;29:468-475.
27. Isojärvi JIT, Pakarinen AJ, Myllylä VV. Thyroid function in epileptic patients treated with carbamazepine. Arch Neurol 1989;46:1175-1178.
28. Isojärvi JIT. Serum steroid hormones and pituitary function in female epileptic patients during carbamazepine therapy. Epilepsia 1990;31:438-445.
29. Herzog AG, Levesque L, Drislane F, et al. Phenytoin-induced elevation of serum oestradiol and reproductive dysfunction in men with epilepsy. Epilepsia 1991;32:550-553.
30. Isojärvi JIT, Laatikainen TJ, Pakarinen AJ, Juntunen KTS, Myllylä VV. Menstrual disorders in women with epilepsy receiving carbamazepine. Epilepsia 1995;36:676-681.
31. Isojärvi JIT, Repo M, Pakarinen AJ, Lukkarinen O, Myllylä VV. Carbamazepine, phenytoin, sex hormones and sexual function in men with epilepsy. Epilepsia 1995;36:366-370.
32. Isojärvi JIT, Laatikainen TJ, Knip M, Pakarinen AJ, Juntunen KTS, Myllylä VV. Obesity and endocrine disorders in women taking valproate for epilepsy. Ann Neurol 1996;39:579-584.
33. Murialdo G, Galimberti CA, Magri F, et al. Menstrual cycle and ovary alterations in women with epilepsy on antiepileptic therapy. J Endocrinol Invest 1997;20:519-526.
34. Isojärvi JIT, Rättyä J, Myllylä VV, et al. Valproate, lamotrigine and insulin-mediated risks in women with epilepsy. Ann Neurol 1998;43:446-451.
35. Murialdo G, Galimberti CA, Gianelli MV, et al. Effects of valproate, phenobarbital and carbamazepine on sex steroid setup in women with epilepsy. Clin Neuropharmacol 1998;21:52-58.
36. Vainionpää LK, Rättyä J, Knip M, et al. Valproate-induced hyperandrogenism during pubertal maturation in girls with epilepsy. Ann Neurol 1999;44:444-450.
37. Rättyä J, Turkka J, Pakarinen AJ, et al. Reproductive endocrine effects of valproate, carbamazepine, and oxcarbazepine in men with epilepsy. Neurology 2001;56:31-36.
38. Laidlaw J. Catamenial epilepsy. Lancet 1956;2:1235-1237.
39. Victor A, Lundberg PO, Johansson EDB. Induction of sex hormone binding globulin by phenytoin. BMJ 1977;2:934-935.
40. Dana-Haeri J, Oxley J, Richens A. Reduction of free testosterone by antiepileptic drugs. BMJ 1982;284:85-86.
41. Margraf JW, Dreifuss FE. Amenorrhea following initiation of therapy with valproic acid. Neurology 1981;31(suppl):S159. Abstract.
42. Levesque LA, Herzog AG, Seibel MM. The effect of phenytoin and carbamazepine on serum dehydroepiandrosterone sulfate in men and women who have partial seizures with temporal lobe involvement. J Clin Endocrinol Metab 1986;63:243-245.
43. Dana-Haeri J, Oxley J, Richens A. Pituitary responsiveness to gonadotrophin-releasing and thyrotrophin-releasing hormones in epileptic patients receiving carbamazepine or phenytoin. Clin Endocrinol 1984;20:163-168.
44. Franceschi M, Perego L, Cavagnini F, et al. Effects of long-term antiepileptic therapy on the hypothalamic-pituitary axis in man. Epilepsia 1984;25:46-52.
45. Perucca E, Hedges A, Makki KA, Ruprah M, Wilson JF, Richens A. A comparative study of the relative enzyme inducing properties of anticonvulsant drugs in epileptic patients. Br J Clin Pharmacol 1984;18:401-410.
46. Morrell MJ. Epilepsy in women: the science of why it is special. Neurology 1999;53(suppl 1):S42-48.
47. Rättyä J, Pakarinen AJ, Knip M, Repo M, Myllylä VV, Isojärvi JIT. Early hormonal changes during valproate or carbamazepine treatment: a 3-month study. Neurology 2001;57:440-444.
48. Isojärvi JIT, Myllylä VV, Pakarinen AJ. Effects of carbamazepine on pituitary responsiveness to luteinizing hormone-releasing hormone, thyrotropin-releasing hormone, and metoclopramide in epileptic patients. Epilepsia 1989;30:50-56.
49. Bauer J, Jarre A, Klingmuller D, Elger CE. Polycystic ovary syndrome in patients with focal epilepsy: a study in 93 women. Epilepsy Res 2000;41:163-167.
50. Isojärvi JIT, Taubøll E, Pakarinen AJ, et al. Altered ovarian function and cardiovascular risk factors in valproate-treated women. Am J Med 2001;111:290-296.
51. Crawford P, Chadwick DJ, Martin C, Tjia J, Back DJ, Orme M. The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids. Br J Clin Pharmacol 1990;30:892-896.
52. Egger J, Brett EM. Effects of sodium valproate in 100 children with special reference to weight. BMJ 1981;29:377-381.
53. Dinesen H, Gram L, Andersen T, et al. Weight gain during treatment with valproate. Acta Neurol Scand 1984;70:65-69.
54. Breum L, Astrup A, Gram L, et al. Metabolic changes during treatment with valproate in humans: implication for untoward weight gain. Metabolism 1992;41:666-670.
55. Gidal BE, Anderson GD, Spencer NW, et al. Valproate-associated weight gain: potential relation to energy expenditure and metabolism in patients with epilepsy. J Epilepsy 1996;9:234-241.
56. Ponchaut S, Veitch K. Valproate and mitochondria. Biochem Pharmacol 1993;46:199-204.
57. Giudice LC. Insulin-like growth factors and ovarian follicular development. Endocrine Rev 1992;13:641-649.
58. Conover CA, Phillip DKL, Kanaley JA, et al. Insulin regulation of insulin-like growth factor binding protein-1 in obese and nonobese humans. J Clin Endocrinol Metab 1992;74:1355-1360.
59. Pasquali R, Casimirri F. The impact of obesity on hyperandrogenism and polycystic ovary syndrome in premenopausal women. Clin Endocrinol 1993;39:1-16.
60. Luef G, Abraham I, Haslinger M, et al. Polycystic ovaries, obesity and insulin resistance in women with epilepsy. A comparative study of carbamazepine and valproic acid in 105 women. J Neurol 2002;249:835-841.
61. Morrell M, Giudice L, Flynn KL, et al. Predictors of ovarian failure in women with epilepsy. Ann Neurol 2002;52:704-711.
62. Hsueh AJW, Adashi EY, Jones PB, Welsh TH Jr. Hormonal regulation of the differentiation of cultured ovarian granulosa cells. Endocrine Rev 1984;5:76-127.
63. Isojärvi JIT, Pakarinen AJ, Rautio A, Pelkonen O, Myllylä VV. Serum sex hormone levels after replacing carbamazepine with oxcarbazepine. Eur J Clin Pharmacol 1995;47:461-464.
64. Isojärvi JIT, Pakarinen AJ, Rautio A, Pelkonen O, Myllylä VV. Liver enzyme induction and serum lipid levels after replacement of carbamazepine with oxcarbazepine. Epilepsia 1994;35:1217-1220.
65. Isojärvi JIT, Airaksinen KEJ, Mustonen JN, et al. Thyroid and myocardial function after replacing carbamazepine by oxcarbazepine. Epilepsia 1995;36:810-816.
66. Patsalos PN, Zakrzewska JM, Elyas AA. Dose dependent enzyme induction by oxcarbazepine? Eur J Clin Pharmacol 1990;39:187-188.
67. Lockard JS, Burkhead-Potter TM, Phillips NK, Congdon WC. Is oxcarbazepine (OCBZ) a contraceptive? Pregnancy rate compared to carbamazepine (CBZ), synthetic CBZ 10-11 epoxide (CBZE), and placebo in monkey. Epilepsia 2000;41(suppl 7):S97-98. Abstract.
68. Klosterskov-Jensen P, Saano V, Haring P, Svenstrup B, Menge GP. Possible interaction between oxcarbazepine and an oral contraceptive. Epilepsia 1992;33:1149-1152.
69. Fattore C, Cipolla G, Gatti G, et al. Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women. Epilepsia 1999;40:783-787.
70. Devinsky O, Vuong A, Hammer A, et al. Stable weight during lamotrigine therapy: a review of 32 studies. Neurology 2000;54:973-975.
71. Biton V, Mirza W, Montouris G, et al. Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy. Neurology 2001;56:172-177.
72. Røste LS, Taubøll E, Berner A, Isojärvi JIT, Gjerstad L. Valproate, but not lamotrigine, induces ovarian morphological changes in Wistar rats. Exp Toxicol Pathol 2001;52:545-552.
73. Bauer J, Isojärvi JIT, Herzog AG, et al. Reproductive dysfunction in women with epilepsy: recommendations for evaluation and management. J Neurol Neurosurg Psychiatry 2002;73:121-125.
74. Conway GS, Jacobs HS. Clinical implications of hyperinsulinemia in women. Clin Endocrinol 1993;39:623-632.
75. Wild RA. Cardiovascular disease risks, insulin resistance, and androgen excess. Semin Reprod Endocrinol 1994;12:38-44.